Brief: Caribou Biosciences Announces The FDA Has Granted Fast Track Designations To CB-010 In Refractory SLE And To CB-012 In Relapsed Or Refractory AML

Caribou Biosciences

03/09/2024 13:37

Sept 3 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES ANNOUNCES THE FDA HAS GRANTED FAST
TRACK
DESIGNATIONS TO CB-010 IN REFRACTORY SLE AND TO CB-012 IN
RELAPSED OR REFRACTORY AML
    * CARIBOU BIOSCIENCES INC: CB-010 GALLOP PHASE 1 TRIAL IN
PATIENTS
WITH LN AND ERL IS ON TRACK TO INITIATE BY YE 2024

Source text for Eikon:  ID:nGNXbRnGNk 
Further company coverage:  CRBU.O 

 ((Reuters.Brief@thomsonreuters.com;))